Skip to main content
. Author manuscript; available in PMC: 2019 Dec 15.
Published in final edited form as: Clin Cancer Res. 2018 Aug 28;24(24):6548–6555. doi: 10.1158/1078-0432.CCR-18-1541

Figure 4. Response to luminespib in a patient with lung adenocarcinoma harboring an EGFR exon 20 insertion mutation.

Figure 4.

A. Positron emission tomography-computed tomography (PET-CT) scans disclosing fluorine-18-fluorodeoxyglucose (FDG) avid lesions (as indicated by white arrows [PET image] and white circles [cross sectional CT image]) in a woman with advanced EGFR-D770_N771insGL mutated lung adenocarcinoma before (baseline) and after luminespib therapy. Decrease in size of lesions is noted. B. Sum of largest target lesions in millimeter (mm) as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 over the course of therapy with luminespib (repeat imaging studies performed at baseline, 6, 12 and 18 weeks prior to progression). Luminespib was started at 70 mg/m2 weekly and then dose-reduced due to toxicity to 54 mg/m2 at week 4 of therapy. The patient achieved a confirmed partial response by RECIST prior to RECIST-based progression at week 18, as indicated.